Yield10 Bioscience Inc (NASDAQ:YTEN) had an increase of 38.68% in short interest. YTEN’s SI was 1.02 million shares in June as released by FINRA. Its up 38.68% from 737,800 shares previously. With 722,300 avg volume, 1 days are for Yield10 Bioscience Inc (NASDAQ:YTEN)’s short sellers to cover YTEN’s short positions. The SI to Yield10 Bioscience Inc’s float is 34.25%. The stock increased 2.11% or $0.03 during the last trading session, reaching $1.45. About 1,886 shares traded. Yield10 Bioscience, Inc. (NASDAQ:YTEN) has declined 61.43% since June 29, 2017 and is downtrending. It has underperformed by 74.00% the S&P500.
The stock of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) hit a new 52-week low and has $0.33 target or 8.00% below today’s $0.36 share price. The 8 months bearish chart indicates high risk for the $24.75M company. The 1-year low was reported on Jun, 29 by Barchart.com. If the $0.33 price target is reached, the company will be worth $1.98 million less. The stock 0.99% or $0 during the last trading session, reaching $0.36. It is down 72.77% since June 29, 2017 and is downtrending. It has underperformed by 85.34% the S&P500. Some Historical ARLZ News: 13/03/2018 – Aralez Pharmaceuticals to Discontinue Yosprala in the U.S; 13/03/2018 – Aralez Pharmaceuticals Sees FY18 Rev $140M-$160M; 13/03/2018 – ARALEZ PHARMACEUTICALS INC ARZ.TO – QTRLY SHR LOSS $0.68; 08/05/2018 – ARALEZ PHARMACEUTICALS INC – COMPANY CAUTIONS THAT IT HAS VERY RECENTLY EXPERIENCED INCREASED GENERIC COMPETITION WITH RESPECT TO TOPROL-XL FRANCHISE; 08/05/2018 – ARALEZ PHARMACEUTICALS INC – FOCUS ON CANADIAN OPERATIONS, SUPPORTED BY TOPROL-XL FRANCHISE REVENUES AND VIMOVO ROYALTIES; 08/05/2018 – ARALEZ PHARMACEUTICALS INC – ARALEZ CANADA WILL FOCUS ON DRIVING ORGANIC GROWTH IN CANADA WITH BLEXTEN AND CAMBIA; 08/05/2018 – ARALEZ – DETERMINED THERE IS REASONABLE POSSIBILITY CO WILL NOT HAVE SUFFICIENT LIQUIDITY TO FUND CURRENT & PLANNED OPERATIONS THROUGH NEXT 12 MONTHS; 08/05/2018 – ARALEZ PHARMACEUTICALS INC – DISCONTINUATION OF U.S. COMMERCIAL OPERATIONS, WITH SIGNIFICANT REDUCTIONS IN OPERATING EXPENSES; 08/05/2018 – ARALEZ PHARMACEUTICALS INC – AS OF MARCH 31, 2018 HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.9 MLN; 14/03/2018 – ARALEZ PHARMACEUTICALS INC – ON MARCH 13, BOARD APPOINTED MICHAEL KASETA AS COMPANY’S CFO – SEC FILING
More news for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) were recently published by: Seekingalpha.com, which released: “Update On Aralez Pharmaceuticals” on June 18, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” and published on June 29, 2018 is yet another important article.
Aralez Pharmaceuticals Inc. operates as a specialty pharmaceutical firm in the United States and Canada. The company has market cap of $24.75 million. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It currently has negative earnings. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.
Analysts await Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) to report earnings on August, 8. They expect $-0.23 earnings per share, up 45.24% or $0.19 from last year’s $-0.42 per share. After $-0.29 actual earnings per share reported by Aralez Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -20.69% EPS growth.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States. The company has market cap of $14.49 million. It is developing various yield traits using proprietary advanced biotechnology trait gene discovery platforms. It currently has negative earnings. The firm was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017.
The post Aralez Pharmaceuticals Inc. (ARLZ) Reaches $0.36 52-Week Low; Yield10 Bioscience (YTEN) Shorts Up By 38.68% appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/06/29/aralez-pharmaceuticals-inc-arlz-reaches-0-36-52-week-low-yield10-bioscience-yten-shorts-up-by-38-68/
No comments:
Post a Comment